Suchergebnisse - "Yuan, Yigang"

PubPharm (6)

1

Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2 : miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

enthalten in: Clinical epigenetics | 2024

von Li, D. | Yuan, Y. | Meng, C. | +11

2

Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

enthalten in: Clinical epigenetics | 2024

von Li, D. | Yuan, Y. | Meng, C. | +11

3

Designing a conjugate vaccine targeting Klebsiella pneumoniae ST258 and ST11

enthalten in: Heliyon | 2024

von Li, M. | Yu, M. | Yuan, Y. | +5

4

Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia

enthalten in: Experimental hematology & oncology | 2024

von Feng, S. | Yuan, Y. | Lin, Z. | +14

5

Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia

enthalten in: Experimental hematology & oncology | 2024

von Feng, S. | Yuan, Y. | Lin, Z. | +14

6

DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax

enthalten in: Theranostics | 2023

von Ye, S. | Xiong, F. | He, X. | +12

1
[1]